DK2086576T3 - H5-proteiner, nukleinsyremolekyler og vektorer kodende for disse, samt medicinsk anvendelse heraf - Google Patents

H5-proteiner, nukleinsyremolekyler og vektorer kodende for disse, samt medicinsk anvendelse heraf

Info

Publication number
DK2086576T3
DK2086576T3 DK07863555.4T DK07863555T DK2086576T3 DK 2086576 T3 DK2086576 T3 DK 2086576T3 DK 07863555 T DK07863555 T DK 07863555T DK 2086576 T3 DK2086576 T3 DK 2086576T3
Authority
DK
Denmark
Prior art keywords
proteins
well
nucleic acid
acid molecules
medical use
Prior art date
Application number
DK07863555.4T
Other languages
English (en)
Inventor
Eric M Vaughn
Paulino Carlos Gonzalez-Hemandez
Juergen Daemmgen
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Application granted granted Critical
Publication of DK2086576T3 publication Critical patent/DK2086576T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK07863555.4T 2006-10-27 2007-10-26 H5-proteiner, nukleinsyremolekyler og vektorer kodende for disse, samt medicinsk anvendelse heraf DK2086576T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86314206P 2006-10-27 2006-10-27
US11/923,326 US8202967B2 (en) 2006-10-27 2007-10-24 H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
PCT/US2007/082699 WO2008052173A2 (en) 2006-10-27 2007-10-26 Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use

Publications (1)

Publication Number Publication Date
DK2086576T3 true DK2086576T3 (da) 2012-10-15

Family

ID=39325469

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07863555.4T DK2086576T3 (da) 2006-10-27 2007-10-26 H5-proteiner, nukleinsyremolekyler og vektorer kodende for disse, samt medicinsk anvendelse heraf

Country Status (18)

Country Link
US (3) US8202967B2 (da)
EP (1) EP2086576B8 (da)
JP (2) JP5442442B2 (da)
KR (2) KR101520307B1 (da)
AU (1) AU2007308869B2 (da)
BR (1) BRPI0718183B8 (da)
CA (1) CA2664914C (da)
CO (1) CO6210831A2 (da)
DK (1) DK2086576T3 (da)
ES (1) ES2391123T3 (da)
MX (1) MX2009004243A (da)
MY (1) MY150226A (da)
PL (1) PL2086576T3 (da)
PT (1) PT2086576E (da)
RU (1) RU2479589C2 (da)
SG (1) SG176419A1 (da)
SI (1) SI2086576T1 (da)
WO (1) WO2008052173A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080065680A (ko) * 2005-10-28 2008-07-14 베링거잉겔하임베트메디카인코퍼레이티드 종 간의 인플루엔자 병원체의 전파를 치료/예방하기 위한백신의 용도
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
DK2134360T3 (da) 2007-03-14 2016-02-22 Takeda Vaccines Inc Oprensning af viruslignende partikel
RU2559527C2 (ru) 2008-11-28 2015-08-10 Мериал Лимитед Рекомбинантная вакцина от птичьего гриппа и её применение
US20110305748A1 (en) * 2010-03-11 2011-12-15 Immune Design, Corp. Vaccines for Pandemic Influenza
BR112013007946B1 (pt) 2010-10-04 2022-07-12 Massachusetts Institute Of Technology Composições farmacêuticas e imunogênicas compreendendo polipeptídeos de hemaglutinina
AR088028A1 (es) * 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
WO2014127825A1 (en) * 2013-02-21 2014-08-28 Boehringer Ingelheim Vetmedica Gmbh H5 proteins of h5n1 influenza virus for use as a medicament
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
JOP20190088A1 (ar) 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
WO2020093984A1 (en) * 2018-11-06 2020-05-14 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition against avian influenza virus h5 subtype
CN117229370B (zh) * 2022-06-08 2024-11-01 中科南京生命健康高等研究院 H5n6禽流感广谱性疫苗的开发及其应用
WO2026013161A1 (en) 2024-07-10 2026-01-15 Boehringer Ingelheim Vetmedica Gmbh Prime and boost vaccination for the treatment and prevention of avian influenza infections in avians
WO2026013162A1 (en) 2024-07-10 2026-01-15 Boehringer Ingelheim Vetmedica Gmbh Herpes virus of turkey vector based h5ha vaccine for the treatment and prevention of avian influenza infections in turkeys

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US382425A (en) 1888-05-08 Brandt
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4552758A (en) 1983-12-20 1985-11-12 St. Jude Children's Research Hospital Human use of avian-human reassortants as vaccines for influenza A virus
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1990001543A1 (fr) 1988-07-29 1990-02-22 Intracel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
ES2116269T3 (es) 1989-03-21 1998-07-16 Vical Inc Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5690938A (en) 1989-07-07 1997-11-25 Oravax, Inc. Oral immunization with multiple particulate antigen delivery system
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
US5643577A (en) 1990-04-24 1997-07-01 The University Of Newcastle Research Associates Limited Oral vaccine comprising antigen surface-associated with red blood cells
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
ATE181108T1 (de) 1991-08-26 1999-06-15 Immuno Ag Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5807722A (en) 1992-10-30 1998-09-15 Bioengineering Resources, Inc. Biological production of acetic acid from waste gases with Clostridium ljungdahlii
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
EP0620277A1 (en) 1993-03-18 1994-10-19 Merck & Co. Inc. Nucleic acid pharmaceuticals
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
ATE475668T1 (de) 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
AU694519B2 (en) 1994-04-29 1998-07-23 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
AU711702B2 (en) 1995-03-23 1999-10-21 Cambridge University Technical Services Limited Vectors for gene delivery
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
MXPA02010642A (es) 2000-04-28 2004-05-17 St Jude Children S Res Hospital Sistema de transfeccion de adn para la generacion de virus de influenza infeccioso.
US20020095197A1 (en) 2000-07-11 2002-07-18 Lardo Albert C. Application of photochemotherapy for the treatment of cardiac arrhythmias
WO2002062381A1 (en) 2001-02-05 2002-08-15 Hisamitsu Pharmaceutical Co., Inc. Baculovirus vector vaccine
US20040219208A1 (en) 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
DE60326369D1 (de) 2002-08-27 2009-04-09 Dow Agrosciences Llc Verwendung von hitzelabilem escherichia-coli-toxin als adjuvans bei geflügel
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
CN1816903B (zh) 2003-07-04 2011-10-05 Nxp股份有限公司 前体溶液及其制备和使用方法
WO2005107797A1 (en) 2004-03-09 2005-11-17 Chiron Corporation Influenza virus vaccines
CA2879182C (en) 2004-05-25 2017-02-14 Medimmune, Inc. Influenza hemagglutinin and neuraminidase variants
CN1748795A (zh) * 2004-09-17 2006-03-22 金宁一 多价禽流感重组活载体疫苗
RU2283139C1 (ru) * 2005-03-21 2006-09-10 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения антигенов для вакцины против вирусов гриппа
KR20080052509A (ko) * 2005-04-11 2008-06-11 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션 유행성 독감 바이러스에 대한 백신
US7871626B2 (en) * 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
JP5714799B2 (ja) 2005-10-18 2015-05-07 ノババックス インコーポレイテッド 機能的インフルエンザウイルス様粒子（ｖｌｐ）
KR20080065680A (ko) * 2005-10-28 2008-07-14 베링거잉겔하임베트메디카인코퍼레이티드 종 간의 인플루엔자 병원체의 전파를 치료/예방하기 위한백신의 용도
US20100150941A1 (en) 2006-09-13 2010-06-17 Dso National Laboratories Hemagglutinin antibody and uses thereof
US8202967B2 (en) * 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
US9555093B2 (en) 2010-04-30 2017-01-31 Temasek Life Sciences Laboratory Limited Universal vaccine against H5N1 lineages
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2014127825A1 (en) 2013-02-21 2014-08-28 Boehringer Ingelheim Vetmedica Gmbh H5 proteins of h5n1 influenza virus for use as a medicament

Also Published As

Publication number Publication date
BRPI0718183B8 (pt) 2022-05-24
ES2391123T3 (es) 2012-11-21
BRPI0718183B1 (pt) 2020-03-17
WO2008052173A3 (en) 2008-11-13
CA2664914C (en) 2016-11-22
EP2086576B1 (en) 2012-07-18
CA2664914A1 (en) 2008-05-02
JP2010508030A (ja) 2010-03-18
KR101520307B1 (ko) 2015-05-29
WO2008052173A8 (en) 2011-02-03
CO6210831A2 (es) 2010-10-20
JP5442442B2 (ja) 2014-03-12
WO2008052173A9 (en) 2012-03-22
SI2086576T1 (sl) 2012-11-30
RU2479589C2 (ru) 2013-04-20
RU2009119597A (ru) 2010-12-10
US20120231027A1 (en) 2012-09-13
WO2008052173A2 (en) 2008-05-02
AU2007308869A1 (en) 2008-05-02
SG176419A1 (en) 2011-12-29
BRPI0718183A2 (pt) 2013-11-05
JP2014012008A (ja) 2014-01-23
EP2086576A2 (en) 2009-08-12
KR20090078362A (ko) 2009-07-17
EP2086576A4 (en) 2011-01-19
US8592558B2 (en) 2013-11-26
KR20150041200A (ko) 2015-04-15
US9375469B2 (en) 2016-06-28
US8202967B2 (en) 2012-06-19
EP2086576B8 (en) 2015-02-18
US20080193471A1 (en) 2008-08-14
MY150226A (en) 2013-12-31
US20140050755A1 (en) 2014-02-20
MX2009004243A (es) 2009-05-14
AU2007308869B2 (en) 2013-10-24
PT2086576E (pt) 2012-10-11
PL2086576T3 (pl) 2012-12-31

Similar Documents

Publication Publication Date Title
DK2086576T3 (da) H5-proteiner, nukleinsyremolekyler og vektorer kodende for disse, samt medicinsk anvendelse heraf
DK2282764T3 (da) Leverspecifikke nukleinsyreregulerende elementer samt fremgangsmåder og anvendelser heraf
EP2037737A4 (en) PROTEINS, NUCLEIC ACIDS FOR THEIR CODING AND CORRESPONDING USES.
DK2617823T3 (da) Phytaser, nukleinsyrer, der koder for disse, og fremgangsmåde til fremstilling og anvendelse heraf
DK2152794T3 (da) Oxygen-fjernende molekyler, artikler indeholdende disse, og fremgangsmåde til deres anvendelse
EP2324045A4 (en) PHOTOVERNETIC NUCLEIC ACID HYDROGEL
EP1987162A4 (en) NUCLEIC ACID ANALYSIS ABOUT SEQUENCE TOKENS
EP2115158A4 (en) DATA PROCESSING AND METHOD OF ANALYZING GENE EXPRESSION DATA TO IDENTIFY ENDOGENOUS REFERENCE GENES
BRPI0814781A2 (pt) Proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico
EP2094175A4 (en) SPINE CROSS CONNECTORS
DK2064334T3 (da) Aldehydtags, anvendelser deraf i site-specifik proteinmodificering
EP1737982A4 (en) NUCLEIC ACID PROGRAMMABLE PROTEIN NETWORKS
IL202443B (en) Nucleic acid encoding it and a pharmaceutical preparation containing the protein, a fusion protein for nucleic acid
BRPI0714876A2 (pt) glucanases, ácidos nucleicos codificando as mesmas e métodos para fabricar e usar as mesmas.
IL230076A0 (en) Certain chemical entities, compositions and methods
DK3067064T3 (da) Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf
EP2780460A4 (en) MODIFIED DNA BINDING PROTEINS AND USES THEREOF
DK2029799T3 (da) Termostabile proteiner og fremgangsmåder til fremstilling og anvendelse heraf
DK1984502T3 (da) Nukleinsyre
DK2190991T3 (da) SDF-1-Bindende nucleinsyrer og anvendelsen deraf
DK1919514T3 (da) Polynucleotider kodende for isoprenoid-modificerende enzymer og fremgangsmåder til anvendelse deraf
PL2140269T3 (pl) Podpis białkowy/znaczniki do wykrywania gruczolakoraka
IL223076A0 (en) Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
EP2212435A4 (en) FUSIONED GENE BZW. FUSIONED GENES
BRPI0810827A2 (pt) Moléculas de anticorpo e ácidos nucleicos